Aspirin Use is Associated with the Reduced Mortality Risk in Chronic Obstructive Pulmonary Disease with Sepsis: a Retrospective Study Using the MIMIC-IV Database

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2024 Nov 18

PMID 39552902

Authors

Zhao Yu

Yuan-Yuan Qian

Affiliations

Soon will be listed here.

Abstract

Background: Sepsis has the characteristics of high morbidity and high mortality in intensive care unit (ICU) patients. Chronic obstructive pulmonary disease (COPD) is an important cause of death. Studies have shown the value of aspirin on COPD and sepsis, separately, but its role in the combined COPD and sepsis patients is unclear. This study aimed to analyze the association of aspirin use after ICU admission with the mortality risk in COPD patients with sepsis.

Methods: We conducted a retrospective study using the Medical Information Mart for Intensive Care (MIMIC)-IV database, enrolling 2,964 COPD patients with sepsis admitted to ICU. They were divided into aspirin users (n=1,642) and non-users (n=1,322). We evaluated the association of aspirin use with in-hospital and 28-day mortality using logistic regression, Kaplan-Meier survival analysis, and Cox proportional-hazards models. The role of aspirin dose and the association of aspirin use with 90-day and 1-year mortality were also assessed.

Results: Aspirin use was associated with lower in-hospital death (13.642% 23.676%) and 28-day mortality (17.296% 30.257%) (P<0.001). Adjusted models confirmed reduced mortality odds ratio (OR) with aspirin use: OR for in-hospital mortality was 0.574 [95% confidence interval (CI): 0.456, 0.721] and 28-day mortality was 0.539 (95% CI: 0.437, 0.665) in model 3. Survival analyses showed higher survival probabilities for aspirin users. Subgroup analyses supported consistent aspirin benefits across various clinical parameters. Additionally, aspirin users had lower 90-day (21.498% 34.191%) and 1-year mortality (27.649% 41.982%) (P<0.001).

Conclusions: Aspirin use is significantly related to in-hospital and 28-day mortality risk in COPD patients with sepsis. This highlighted the clinical relevance of aspirin in COPD patients with sepsis.

References

Xl L, Gy Z, R G, N C . Ferroptosis in sepsis: The mechanism, the role and the therapeutic potential. Front Immunol. 2022; 13:956361. PMC: 9389368. DOI: 10.3389/fimmu.2022.956361. View

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Antoniu S, Mihaescu T . Hospitalizations and mortality in the Lung Health Study. Expert Rev Pharmacoecon Outcomes Res. 2009; 2(6):523-6. DOI: 10.1586/14737167.2.6.523. View

Goto T, Faridi M, Camargo C, Hasegawa K . The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study. NPJ Prim Care Respir Med. 2018; 28(1):7. PMC: 5821863. DOI: 10.1038/s41533-018-0074-x. View

Wang Y, Ouyang Y, Liu B, Ma X, Ding R . Platelet activation and antiplatelet therapy in sepsis: A narrative review. Thromb Res. 2018; 166:28-36. DOI: 10.1016/j.thromres.2018.04.007. View

Xie J, Wang H, Kang Y, Zhou L, Liu Z, Qin B . The Epidemiology of Sepsis in Chinese ICUs: A National Cross-Sectional Survey. Crit Care Med. 2019; 48(3):e209-e218. DOI: 10.1097/CCM.0000000000004155. View

Ahlstrom B, Frithiof R, Larsson I, Strandberg G, Lipcsey M, Hultstrom M . A comparison of impact of comorbidities and demographics on 60-day mortality in ICU patients with COVID-19, sepsis and acute respiratory distress syndrome. Sci Rep. 2022; 12(1):15703. PMC: 9487845. DOI: 10.1038/s41598-022-19539-0. View

Campo G, Pavasini R, Malagu M, Mascetti S, Biscaglia S, Ceconi C . Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015; 29(2):147-57. DOI: 10.1007/s10557-014-6569-y. View

Eisen D, Moore E, Leder K, Lockery J, McBryde E, McNeil J . AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol. BMJ Open. 2017; 7(1):e013636. PMC: 5253551. DOI: 10.1136/bmjopen-2016-013636. View

10.

Huang M, Cai S, Su J . The Pathogenesis of Sepsis and Potential Therapeutic Targets. Int J Mol Sci. 2019; 20(21). PMC: 6862039. DOI: 10.3390/ijms20215376. View

11.

Cox D . Sepsis - it is all about the platelets. Front Immunol. 2023; 14:1210219. PMC: 10282552. DOI: 10.3389/fimmu.2023.1210219. View

12.

Pan S, Lv Z, Wang R, Shu H, Yuan S, Yu Y . Sepsis-Induced Brain Dysfunction: Pathogenesis, Diagnosis, and Treatment. Oxid Med Cell Longev. 2022; 2022:1328729. PMC: 9433216. DOI: 10.1155/2022/1328729. View

13.

Hsu W, Porta L, Chang I, Dao Q, Tehrani B, Hsu T . Association Between Aspirin Use and Sepsis Outcomes: A National Cohort Study. Anesth Analg. 2022; 135(1):110-117. DOI: 10.1213/ANE.0000000000005943. View

14.

Lavie I, Lavie M, Gafter-Gvili A, Halperin E, Abramovich-Yoffe H, Avni T . Chronic aspirin use and survival following sepsis-A propensity-matched, observational cohort study. Clin Microbiol Infect. 2022; 28(9):1287.e1-1287.e7. DOI: 10.1016/j.cmi.2022.04.010. View

15.

Liu Y, Yao Y, Yu M, Gao Y, Qi A, Jiang T . Frequency and mortality of sepsis and septic shock in China: a systematic review and meta-analysis. BMC Infect Dis. 2022; 22(1):564. PMC: 9210671. DOI: 10.1186/s12879-022-07543-8. View

16.

Heung M, Koyner J . Entanglement of sepsis, chronic kidney disease, and other comorbidities in patients who develop acute kidney injury. Semin Nephrol. 2015; 35(1):23-37. DOI: 10.1016/j.semnephrol.2015.01.004. View

17.

Chen S, Li S, Kuang C, Zhong Y, Yang Z, Yang Y . Aspirin reduces the mortality risk of sepsis-associated acute kidney injury: an observational study using the MIMIC IV database. Front Pharmacol. 2023; 14:1186384. PMC: 10407089. DOI: 10.3389/fphar.2023.1186384. View

18.

Yayan J . No significant detectable anti-infection effects of aspirin and statins in chronic obstructive pulmonary disease. Int J Med Sci. 2015; 12(3):280-7. PMC: 4366633. DOI: 10.7150/ijms.11054. View

19.

Chen Y, Lu L, Li X, Liu B, Zhang Y, Zheng Y . Association between chronic obstructive pulmonary disease and 28-day mortality in patients with sepsis: a retrospective study based on the MIMIC-III database. BMC Pulm Med. 2023; 23(1):435. PMC: 10633936. DOI: 10.1186/s12890-023-02729-5. View

20.

Wang Y, Wang M, Liu C, Hao M, Wang W, Li Y . Hepatoprotective effects of aspirin on diethylnitrosamine-induced hepatocellular carcinoma in rats by reducing inflammation levels and PD-L1 expression. Sci Rep. 2023; 13(1):21362. PMC: 10695938. DOI: 10.1038/s41598-023-48812-z. View